Cargando…

Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review

BACKGROUND: Despite more than 60 years of clinical trials, tuberculosis (TB) still causes a high global burden of mortality and morbidity. Treatment currently requires multiple drugs in combination, taken over a prolonged period. New drugs are needed to shorten treatment duration, prevent resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonnett, Laura Jayne, Ken-Dror, Gie, Davies, Geraint Rhys
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822642/ https://www.ncbi.nlm.nih.gov/pubmed/29467027 http://dx.doi.org/10.1186/s13063-018-2522-x

Ejemplares similares

Quality of outcome reporting in phase II studies in pulmonary tuberculosis
por: Bonnett, Laura Jayne, et al.
Publicado: (2015)

Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials
por: Bonnett, Laura J, et al.
Publicado: (2017)

Reported outcomes in phase II studies of newly-diagnosed pulmonary tuberculosis
por: Bonnett, Laura J, et al.
Publicado: (2015)

The impact of inclusion, dose and duration of pyrazinamide (PZA) on efficacy and safety outcomes in tuberculosis: systematic review and meta-analysis protocol
por: Millard, James D., et al.
Publicado: (2019)

Short- versus long-term outcomes after treatment for tuberculosis
por: Bonnett, Laura, et al.
Publicado: (2013)

Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs
por: Davies, Geraint, et al.
Publicado: (2019)

Markov chain Monte Carlo Gibbs sampler approach for estimating haplotype frequencies among multiple malaria infected human blood samples
por: Ken-Dror, Gie, et al.
Publicado: (2021)

Markov chain Monte Carlo and expectation maximization approaches for estimation of haplotype frequencies for multiply infected human blood samples
por: Ken-Dror, Gie, et al.
Publicado: (2016)

Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies
por: Waitt, Catriona John, et al.
Publicado: (2015)

Pathophysiology, diagnosis and management of cerebral venous thrombosis: A comprehensive review
por: Ranjan, Redoy, et al.
Publicado: (2023)

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
por: Pillay, Samantha, et al.
Publicado: (2022)

Access to quality diagnosis and rational treatment for tuberculosis: real-world evidence from China–Gates Tuberculosis Control Project Phase III
por: Li, Zhi-Peng, et al.
Publicado: (2021)

Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis
por: Kloprogge, Frank, et al.
Publicado: (2020)

STUDIES ON ENDOTHELIAL REACTIONS : III. THE ENDOTHELIUM IN EXPERIMENTAL PULMONARY TUBERCULOSIS.
por: Foot, Nathan Chandler
Publicado: (1920)

Stool Culture for Diagnosis of Pulmonary Tuberculosis in Children
por: Walters, Elisabetta, et al.
Publicado: (2017)

Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis
por: Sloan, Derek J., et al.
Publicado: (2015)

Perceptions of Research Bronchoscopy in Malawian Adults with Pulmonary Tuberculosis: A Cross-Sectional Study
por: McCallum, Andrew D., et al.
Publicado: (2016)

A systematic review of the quality of conduct and reporting of survival analyses of tuberculosis outcomes in Africa
por: Ngari, Moses M., et al.
Publicado: (2021)

Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review
por: Komorowski, Adam S., et al.
Publicado: (2020)

A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials
por: Hills, N. K., et al.
Publicado: (2021)

Kinetics of Mycobacterium tuberculosis-specific IFN-γ responses and sputum bacillary clearance in HIV-infected adults during treatment of pulmonary tuberculosis
por: Mzinza, David T., et al.
Publicado: (2015)

Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults
por: Peetluk, Lauren S., et al.
Publicado: (2021)

Effect of pulmonary hypertension on outcome of pulmonary tuberculosis
por: Marjani, Majid, et al.
Publicado: (2014)

Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB
por: Barr, David A., et al.
Publicado: (2016)

Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation
por: Millard, James, et al.
Publicado: (2018)

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis
por: Sloan, Derek J., et al.
Publicado: (2017)

Unite all the services against childhood tuberculosis
por: Gie, R.P.
Publicado: (2016)

4298 Prediction models for pulmonary tuberculosis treatment outcomes: a systematic review
por: Peetluk, Lauren Saag, et al.
Publicado: (2020)

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
por: Imperial, Marjorie Z., et al.
Publicado: (2018)

Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies
por: Sivendran, Shanthi, et al.
Publicado: (2015)

Continuous positive airway pressure therapy reduces the levels of catecholamines and blood pressure in pseudophaeochromocytoma with coexisting obstructive sleep apnoea
por: Ken-Dror, Gie, et al.
Publicado: (2021)

Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2019)

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape
por: Phillips, Patrick P. J., et al.
Publicado: (2019)

Cash interventions to improve clinical outcomes for pulmonary tuberculosis: systematic review and meta-analysis
por: Richterman, Aaron, et al.
Publicado: (2018)

Reform in Tuberculosis Work: III. The Tuberculosis Officer
Publicado: (1917)

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
por: Imperial, Marjorie Z., et al.
Publicado: (2018)

Health‐related quality of life in stage III‐IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials
por: Chen, Chen, et al.
Publicado: (2022)

Reporting of PPI and the MCID in phase III/IV randomised controlled trials—a systematic review
por: Brennan, Joseph, et al.
Publicado: (2023)

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
por: Nilsson, S., et al.
Publicado: (2016)

547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir
por: Proudfoot, Clare, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6cslkvqlpghbh0bp2cr4abnn0r